With the risk of diversion potentially greater than it was before the pandemic, these data should be viewed as a warning sign.
Tom Knight, CEO, Invistics
Advertisement
Articles by Tom Knight, CEO, Invistics
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
ACIP's Vacancy Leaves Pharmacists Navigating COVID-19 Confusion
2
COVID-19 in 2026: Why the Virus Still Threatens Vulnerable Patients
3
Why Advocacy Is Essential for Independent Pharmacy Survival
4
FDA-Approved Sunscreen Filter Bemotrizinol Debuts in New US Products
5